Skip to main content
. 2016 Dec 30;14(4):205–210. doi: 10.5808/GI.2016.14.4.205

Table 2. HRs of clinical characteristics of patients with B-cell lymphoma treated by R-CHOP for overall survival and progression-free survival (n = 90).

graphic file with name gni-14-205-i002.jpg

HR, hazard ratio; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; CI, confidence interval; IPI, International Prognostic Index.